SCHEMBL6049519

SCHEMBL6049519

Nc1nc(N)c(-c2cccc(Cl)c2Cl)c(COc2ccccc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 2/20 0.57
DHFR P00374 11/20 0.54
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CYP2D6 P10635 2/20 0.45
MAOA P21397 1/20 0.45
MAPK1 P28482 1/20 0.45
ADRA1A P35348 1/20 0.45
SCN4A P35499 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
PDE3A Q14432 1/20 0.45
SCN5A Q14524 1/20 0.45
SCN9A Q15858 1/20 0.45
SCN2A Q99250 1/20 0.45
SCN3A Q9NY46 1/20 0.45
SCN10A Q9Y5Y9 1/20 0.45
GHSR Q92847 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072676 0.84 CYP2D6 (0.47) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL29384947 0.80 CYP2D6 (0.50) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL310324 0.80 CYP2D6 (0.50) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL6049486 0.80 CYP2D6 (0.50) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL6049489 0.80 HEXA (0.62) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
Hydrochloric Acid SCHEMBL7767228 0.79 CYP2D6 (0.49) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL5566857 0.77 CYP2D6 (0.48) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL14813234 0.77 CYP1A2 (0.63) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL5069251 0.76 HEXA (0.48) CYP1A2CYP3A4DHFRSMN1; SMN2CYP2D6
SCHEMBL6049459 0.72 CYP2D6 (0.54) CYP2D6MAOAMAPK1ADRA1ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0715851-B1 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders WELLCOME FOUND (GB) 2003-04-02 EP claimed
US-5597828-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY GLAXO WELLCOME INC. (US) 1997-01-28 US claimed
EP-1681058-A2 Pharmacologically active cns compounds THE WELLCOME FOUNDATION LIMITED (GB) 2006-07-19 EP disclosed
EP-1325916-A1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system THE WELLCOME FOUNDATION LIMITED (GB) 2003-07-09 EP disclosed
EP-0715851-B1 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders WELLCOME FOUND (GB) 2003-04-02 EP disclosed
US-5712276-A TREATING NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. (US) 1998-01-27 US disclosed
US-5684005-A PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE GLAXO WELLCOME INC. (US) 1997-11-04 US disclosed
US-5635507-A PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER GLAXO WELLCOME INC. (US) 1997-06-03 US disclosed
US-5597828-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY GLAXO WELLCOME INC. (US) 1997-01-28 US disclosed
US-5597827-A CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. 1997-01-28 US disclosed
US-5591746-A GLUTAMATE INHIBITORS; CENTRAL NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. 1997-01-07 US disclosed
EP-0727213-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727214-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727212-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0715851-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-06-12 EP disclosed
EP-0713703-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-05-29 EP disclosed
CN-1113487-A Method for preparing pharmaceutically active CNS compounds WELLCOME FOUND (GB) 1995-12-20 CN disclosed
US-5136080-A Intermediates for glutamate inhibitors BURROUGHS WELLCOME CO. (US) 1992-08-04 US disclosed
CN-1052306-A Compounds having pharmacological activity on the central nervous system WELLCOME FOUND (GB) 1991-06-19 CN disclosed
EP-0372934-A2 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-13 EP disclosed